Adaptive Biotechnologies Corp vs Domino's Pizza, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Domino's Pizza, Inc. trades at $356.34 (market cap $11.82B). The key difference: Domino's Pizza, Inc. is far larger — about 2.9× Adaptive Biotechnologies Corp's market cap, and Domino's Pizza, Inc. pays a 2.23% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | DPZ | |
|---|---|---|
Market Cap | $4.04B | $11.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $467.30 |
52-Week Low | $12.30 | $282.89 |
Enterprise Value | $4.10B | $16.78B |
Dividend Yield | — | 2.23% |
Trailing returns across standard periods
Latest headlines on both assets
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →